ClinicalTrials.gg
TerminatedNCT05764265Updated Jan 27, 2026Results posted

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

A Phase 2 interventional study of LTP001 in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 12 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
6th of 12
31 · median 27
Started
2023
the only one that year
Phase 2
5 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 2, and was the 11th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH). The study offered participants who had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in CLTP001A12201 was generally not needed but could occur on request by the investigator.

Read the detailed description

This was a non-randomized, open-label extension study of LTP001 for participants with PAH who completed the parent Study CLTP001A12201. Eligible participants were presented with the opportunity to enroll in the extension study at the end of treatment visit of the parent study. Participants in the extension study were planned to receive a once-daily dose of LTP001 for 52 weeks regardless of their parent study treatment (i.e. LTP001 or placebo). The study duration was planned up to 54 weeks with a treatment duration up to 52 weeks and maximum 2-week transition period from the CLTP001A12201 study. The visit frequency was planned to include visits at Weeks 1, 5, 13, 26, 39, 52, and 54 along with optional visits at the discretion of the Investigators at Weeks 9 and 17.

Due to the study termination, no patient reached Week 52. After the termination announcement, following the instruction to immediately stop treatment for all participants, an end-of-treatment (EOT) visit was conducted. Sites were advised to complete protocol-required assessments based on investigator judgement and patient willingness to undergo procedures, with a primary focus on ensuring a safe exit from the study. Most sites performed only a few safety assessments, and only a minimal number of patients completed an echocardiogram.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must have been obtained before any assessment was performed.
  • Participant was currently completing the Novartis-sponsored study CLTP001A12201 in PAH and completed key efficacy and safety procedures up to the end of treatment of the core study, without meeting discontinuation criteria in the core study.
  • Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
  • In the opinion of the Investigator would benefit from LTP001 treatment.

Exclusion criteria

Exclusion Criteria:

  • History of to the study treatment.
  • Sexually active males not committing to condom use precautions: sexually active males must have used a condom during intercourse while taking drug and for 24 hours after stopping study medication and should not father a child in this period nor donate sperm. A condom was required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
  • Required or planned transplant or heart/lung surgery.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of while taking study treatment and until EOT visit (2 weeks post-last treatment). Highly effective contraception methods included:
  • Total abstinence (when this was in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal were not acceptable methods of contraception.
  • Female sterilization (had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment.
  • Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should have been the sole partner for that participant
  • Use of oral, estrogen and progesterone, injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

Women were considered if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women were considered not of child-bearing potential if they were post-menopausal or had surgical bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks prior. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment was she considered not of child bearing potential.

  • Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Acute or chronic impairment (other than dyspnea), which would limit the ability to comply with study requirements, including interference with physical activity or execution of study procedures such as 6MWT (e.g., angina pectoris, claudication, musculoskeletal disorder, need for walking aids).
  • Permanent discontinuation of Novartis drug in the core efficacy study due to toxicity or disease progression despite active treatment, non-compliance to study procedures, withdrawal of consent or any other reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    LTP001

    Participants received LTP001, 6 mg, orally once daily in the morning for approximately 39 weeks

    Drug: LTP001

Interventions

  • DrugLTP001

    LTP001, 6 mg, was administered orally once daily in the morning

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and severity of adverse events (AEs) by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs. Due to the study termination, no patient reached Week 52. At the end of treatment visit, final safety assessments were performed.

    Time frame: Up to approximately 45 weeks

Secondary outcomes

  1. Change From Baseline in Average Cardiac Output (CO) at Week 26

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including CO.

    Time frame: Baseline, Week 26

  2. Change From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 26

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including PA pressure.

    Time frame: Baseline, Week 26

  3. Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26

    Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).

    Time frame: Baseline, Week 26

  4. Change From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26

    PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dynes.sec.cm-5.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Right Atrium (RA) Pressures at Week 26

    The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.

    Time frame: Baseline, Week 26

  6. Change From Baseline in Systemic Vascular Resistance (SVR) at Week 26

    The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including SVR.

    Time frame: Baseline, Week 26

  7. Change From Baseline in Six Minute Walk Distance (6MWD)

    6MWD test measures the distance that a participant can walk on a flat, hard surface in a period of 6 minutes. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

    Time frame: Baseline, Week 26, up to 39 weeks (EOT)

  8. Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

    Time frame: Baseline, Week 26, up to 39 weeks (EOT)

  9. Change From Baseline in Tricuspid Annular Plane Systolic Velocity (TASV)

    Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

    Time frame: Baseline, Week 26, up to 39 weeks (EOT)

  10. Change From Baseline in Peak Velocity of Excursion (RV S')

    Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

    Time frame: Baseline, Week 26, up to 39 weeks (EOT)

  11. Change From Baseline in Fractional Area Change (FAC)

    Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

    Time frame: Baseline, Week 26, up to 39 weeks (EOT)

  12. Change From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire

    emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

    Time frame: Baseline up to 39 weeks (EOT)

  13. Change From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire

    PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

    Time frame: Baseline up to 39 weeks (EOT)

  14. Time to Clinical Worsening

    Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six-minute walk distance Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

    Time frame: Baseline up to 39 weeks (EOT)

  15. Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)

    NT-proBNP is a blood biomarker to assess right ventricular distress. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

    Time frame: Baseline up to 39 weeks (EOT)

07

Results

Posted Dec 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Started238
Completed00
Not completed238
Withdrew: Adverse event10
Withdrew: Physician decision18
Withdrew: Study terminated by sponsor200
Withdrew: Participant decision10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Incidence and severity of adverse events (AEs) by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs. Due to the study termination, no patient reached Week 52. At the end of treatment visit, final safety assessments were performed.

Time frame:
Up to approximately 45 weeks
Reported as:
Number · Percentage of participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
AEs52.262.5
Serious AEs17.40
SecondaryChange From Baseline in Average Cardiac Output (CO) at Week 26

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including CO.

Time frame:
Baseline, Week 26
Reported as:
Mean · liters per minute
Change From Baseline in Average Cardiac Output (CO) at Week 26
liters per minuteLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Average Cardiac Output (CO) at Week 26-0.111 ± 0.2153-0.065 ± 0.5916
SecondaryChange From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 26

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including PA pressure.

Time frame:
Baseline, Week 26
Reported as:
Mean · mmHg
Change From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 26
mmHgLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 263.8 ± 8.18-1.5 ± 7.78
SecondaryChange From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26

Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).

Time frame:
Baseline, Week 26
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26
mmHgLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26-1.0 ± 1.79-0.5 ± 0.71
SecondaryChange From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26

PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dynes.sec.cm-5.

Time frame:
Baseline, Week 26
Reported as:
Mean · dynes.sec.cm-5
Change From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26
dynes.sec.cm-5LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26100.058 ± 95.5879-7.445 ± 34.8250
SecondaryChange From Baseline in Right Atrium (RA) Pressures at Week 26

The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.

Time frame:
Baseline, Week 26
Reported as:
Mean · mmHg
Change From Baseline in Right Atrium (RA) Pressures at Week 26
mmHgLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Right Atrium (RA) Pressures at Week 26-1.5 ± 6.220.0 ± 2.83
SecondaryChange From Baseline in Systemic Vascular Resistance (SVR) at Week 26

The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including SVR.

Time frame:
Baseline, Week 26
Reported as:
Mean · dynes.sec.cm-5
Change From Baseline in Systemic Vascular Resistance (SVR) at Week 26
dynes.sec.cm-5LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Systemic Vascular Resistance (SVR) at Week 26166.748 ± 128.6202-49.710 ± 28.5388
SecondaryChange From Baseline in Six Minute Walk Distance (6MWD)

6MWD test measures the distance that a participant can walk on a flat, hard surface in a period of 6 minutes. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

Time frame:
Baseline, Week 26, up to 39 weeks (EOT)
Reported as:
Mean · meters
Change From Baseline in Six Minute Walk Distance (6MWD)
metersLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Week 26 n=6,2-33.7 ± 55.60-9.0 ± 25.46
EOT n=16,2-6.3 ± 50.21-1.0 ± 1.41
SecondaryChange From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)

Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

Time frame:
Baseline, Week 26, up to 39 weeks (EOT)
Reported as:
Mean · centimeters
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)
centimetersLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Week 26 n=6,20.03 ± 0.1750.00 ± 0.283
EOT n=7,00.01 ± 0.682—
SecondaryChange From Baseline in Tricuspid Annular Plane Systolic Velocity (TASV)

Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

Time frame:
Baseline, Week 26, up to 39 weeks (EOT)
Reported as:
Mean · centimeters per second
Change From Baseline in Tricuspid Annular Plane Systolic Velocity (TASV)
centimeters per secondLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Week 26 n=6,2-2.2 ± 3.43-0.5 ± 0.71
EOT n=7,0-2.6 ± 1.90—
SecondaryChange From Baseline in Peak Velocity of Excursion (RV S')

Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

Time frame:
Baseline, Week 26, up to 39 weeks (EOT)
Reported as:
Mean · centimeters per second
Change From Baseline in Peak Velocity of Excursion (RV S')
centimeters per secondLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Week 26 n=6,2-2.2 ± 3.43-0.5 ± 0.71
EOT n=7,0-2.6 ± 1.90—
SecondaryChange From Baseline in Fractional Area Change (FAC)

Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).

Time frame:
Baseline, Week 26, up to 39 weeks (EOT)
Reported as:
Mean · percent
Change From Baseline in Fractional Area Change (FAC)
percentLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Week 26 n=6,1-0.87 ± 6.1627.30 ± NA
EOT n=6,00.97 ± 5.290—
SecondaryChange From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire

emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

Time frame:
Baseline up to 39 weeks (EOT)
Reported as:
Mean · score
Change From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire
scoreLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire1.476 ± 2.32261.000 ± NA
SecondaryChange From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire

PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

Time frame:
Baseline up to 39 weeks (EOT)
Reported as:
Mean · score
Change From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire
scoreLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire2.929 ± 2.3234-0.833 ± NA
SecondaryTime to Clinical Worsening

Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six-minute walk distance Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

Time frame:
Baseline up to 39 weeks (EOT)
Reported as:
Median · days
Time to Clinical Worsening
daysLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Time to Clinical Worsening346.0 (187.0 to NA)—
SecondaryChange From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)

NT-proBNP is a blood biomarker to assess right ventricular distress. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.

Time frame:
Baseline up to 39 weeks (EOT)
Reported as:
Mean · picomoles per liter
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)
picomoles per literLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)3.832 ± 31.22557.250 ± 16.6033

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 6 weeks post treatment, up to approximately 45 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTP001 6 mg (Actual Treatment in CLTP001A12201)0/23 (0%)4/23 (17.4%)5/23 (21.7%)
LTP001 6 mg (Placebo in CLTP001A12201)0/8 (0%)0/8 (0%)5/8 (62.5%)
Total0/31 (0%)4/31 (12.9%)10/31 (32.3%)
Most frequent serious events
Most frequent serious events
EventLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders2/230/82/31
Medical device site haemorrhageGeneral disorders and administration site conditions1/230/81/31
Device related infectionInfections and infestations1/230/81/31
Disseminated gonococcal infectionInfections and infestations1/230/81/31
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
LymphadenopathyBlood and lymphatic system disorders0/231/81/31
Eczema eyelidsEye disorders0/231/81/31
FatigueGeneral disorders and administration site conditions0/231/81/31
BartholinitisInfections and infestations0/231/81/31
BronchitisInfections and infestations0/231/81/31
NasopharyngitisInfections and infestations2/231/83/31
Tooth abscessInfections and infestations0/231/81/31
Musculoskeletal painMusculoskeletal and connective tissue disorders0/231/81/31
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/231/81/31
DizzinessNervous system disorders0/231/81/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
Mean47.0 ± 11.7648.4 ± 13.3547.4 ± 11.97
Age, Customized
Age, Customized(Participants)LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
18 - <6520727
65 - <85314
Sex: Female, Male
Sex: Female, Male(Participants)LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
Female21627
Male224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LTP001 6 mg (Actual Treatment in CLTP001A12201)LTP001 6 mg (Placebo in CLTP001A12201)Total
White21728
American Indian or Alaskan202
Asian011
08

Study locations

12 sites
  • Pulmonary Associates PA
    Mesa, Arizona 85206, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1025ABI, Argentina
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Amsterdam, North Holland 1081 HV, Netherlands
  • Novartis Investigative Site
    Krakow, 31 202, Poland
  • Novartis Investigative Site
    Lodz, 91-347, Poland
  • Novartis Investigative Site
    Wroclaw, 50-556, Poland
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Málaga, 29010, Spain
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Apr 2024, 12 months.

Results were first posted in Dec 2025, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Mar 10, 2023
StartActual
Mar 27, 2023
Primary completionActual
Apr 26, 2024
CompletionActual
May 14, 2024
Results first posted
Dec 26, 2025
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05764265
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Mar 27, 2023
Primary completion
Apr 26, 2024
Completion
May 14, 2024
Results posted
Dec 26, 2025
Last update
Jan 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTP001

Start the discussion